| Q36732888 | A germline variant N375S in MET and gastric cancer susceptibility in a Chinese population |
| Q54390371 | A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. |
| Q34445648 | Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization |
| Q34668730 | Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (Review). |
| Q35041171 | C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis |
| Q37466336 | Cancer therapy using tumor-associated antigens to reduce side effects |
| Q38263841 | Clinical management of advanced gastric cancer: the role of new molecular drugs. |
| Q90353134 | Clinical significance of MET gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy |
| Q26776190 | Clinical significance of MET in gastric cancer |
| Q88747502 | Correlation between HGF/c-Met and Notch1 signaling pathways in human gastric cancer cells |
| Q90702159 | Current advances of targeting HGF/c-Met pathway in gastric cancer |
| Q38816624 | Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer. |
| Q42803000 | Establishment and characterization of three novel human gastric cancer cell lines with differentiated intestinal phenotype derived from liver metastasis |
| Q35677873 | Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression |
| Q54645357 | Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal Adenocarcinoma |
| Q33643400 | Expression of MACC1 and c-Met in human gastric cancer and its clinical significance |
| Q47117947 | Expression of c-Met and hepatocyte growth factor in various gastric pathologies and its association with Helicobacter pylori infection |
| Q27028079 | Gastric Cancer: New Drugs - New Strategies |
| Q37442676 | Gastric cancer in the era of molecularly targeted agents: current drug development strategies |
| Q53570632 | Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. |
| Q38241766 | How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer |
| Q28253680 | Invasive growth: a MET-driven genetic programme for cancer and stem cells |
| Q36949256 | MET expression and amplification in patients with localized gastric cancer |
| Q36089948 | MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome |
| Q46799794 | MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas |
| Q37735662 | MET4 expression predicts poor prognosis of gastric cancers with Helicobacter pylori infection |
| Q26798420 | Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy |
| Q37962816 | Molecular targeted agents for gastric and gastroesophageal junction cancer |
| Q38632917 | Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives |
| Q36654661 | Over-expression of Metastasis-associated in Colon Cancer-1 (MACC1) Associates with Better Prognosis of Gastric Cancer Patients |
| Q39080592 | Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. |
| Q27320322 | Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer |
| Q39038837 | Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients |
| Q34446136 | Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients |
| Q39511886 | Recombinant immunotoxin anti-c-Met/PE38KDEL inhibits proliferation and promotes apoptosis of gastric cancer cells |
| Q40004623 | Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma |
| Q37719332 | Strategies for treating liver metastasis from gastric cancer |
| Q36097149 | Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity |
| Q38856729 | Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges |
| Q34173500 | The Met oncogene and basal-like breast cancer: another culprit to watch out for? |
| Q55069791 | The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer. |
| Q36127679 | The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays |
| Q37302936 | The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study |
| Q37621003 | The function, proteolytic processing, and histopathology of Met in cancer |